| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 176,032 | 220,449 | ||
| Short-term marketable securities | 561,794 | 521,866 | ||
| Prepaid expenses and other current assets | 16,709 | 22,285 | ||
| Total current assets | 754,535 | 764,600 | ||
| Long-term marketable securities | 250,490 | 343,931 | ||
| Right of use asset | 552 | 621 | ||
| Total assets | 1,005,577 | 1,109,152 | ||
| Accounts payable | 20,399 | 13,249 | ||
| Loan payable, current | - | 13,501 | ||
| Accrued expenses and other current liabilities | 27,252 | 33,651 | ||
| Total current liabilities | 47,651 | 60,401 | ||
| Operating lease liability, noncurrent | 289 | 372 | ||
| Loan payable, noncurrent | - | 22,160 | ||
| Warrant liability | - | 400 | ||
| Total liabilities | 47,940 | 83,333 | ||
| Common stock, 0.0001 par value, 150,000,000 shares authorized as of september 30, 2025 and december 31, 2024 80,149,218 and 72,383,013 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 8 | 8 | ||
| Additional paid-in capital | 2,004,755 | 1,992,209 | ||
| Accumulated other comprehensive income | 1,826 | 988 | ||
| Accumulated deficit | -1,048,952 | -967,386 | ||
| Total stockholders' equity | 957,637 | 1,025,819 | ||
| Total liabilities and stockholders' equity | 1,005,577 | 1,109,152 | ||
Akero Therapeutics, Inc. (AKRO)
Akero Therapeutics, Inc. (AKRO)